MX2024000872A - Tratamiento de la nefropatia membranosa mediada por autoanticuerpos anti-pla2r. - Google Patents
Tratamiento de la nefropatia membranosa mediada por autoanticuerpos anti-pla2r.Info
- Publication number
- MX2024000872A MX2024000872A MX2024000872A MX2024000872A MX2024000872A MX 2024000872 A MX2024000872 A MX 2024000872A MX 2024000872 A MX2024000872 A MX 2024000872A MX 2024000872 A MX2024000872 A MX 2024000872A MX 2024000872 A MX2024000872 A MX 2024000872A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- mediated
- membranous nephropathy
- pla2r
- pla2r autoantibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21186299 | 2021-07-19 | ||
| EP21203870 | 2021-10-21 | ||
| PCT/EP2022/070162 WO2023001804A1 (en) | 2021-07-19 | 2022-07-19 | Treatment of anti-pla2r autoantibody-mediated membranous nephropathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024000872A true MX2024000872A (es) | 2024-02-09 |
Family
ID=82851755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024000872A MX2024000872A (es) | 2021-07-19 | 2022-07-19 | Tratamiento de la nefropatia membranosa mediada por autoanticuerpos anti-pla2r. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240343822A1 (https=) |
| EP (1) | EP4373574A1 (https=) |
| JP (1) | JP2024525870A (https=) |
| KR (1) | KR20240035816A (https=) |
| AU (1) | AU2022315512A1 (https=) |
| CA (1) | CA3225908A1 (https=) |
| CL (2) | CL2024000146A1 (https=) |
| IL (1) | IL309940A (https=) |
| MX (1) | MX2024000872A (https=) |
| TW (1) | TW202321303A (https=) |
| WO (1) | WO2023001804A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116535510B (zh) * | 2023-06-30 | 2023-11-10 | 四川省医学科学院·四川省人民医院 | 一种抗人pla2r的抗体、试剂盒及其应用 |
| WO2025254179A1 (en) * | 2024-06-06 | 2025-12-11 | Chugai Seiyaku Kabushiki Kaisha | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| WO1999062526A2 (en) | 1998-06-05 | 1999-12-09 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to cd38 to treat multiple myeloma |
| US7223397B1 (en) | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
| EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
| KR20140066259A (ko) | 2004-02-06 | 2014-05-30 | 모르포시스 아게 | 항-ｃｄ３８ 인간 항체 및 그의 용도 |
| JP5225069B2 (ja) | 2005-03-23 | 2013-07-03 | ゲンマブ エー／エス | 多発性骨髄腫の治療のためのｃｄ３８に対する抗体 |
| TW200745162A (en) | 2005-05-24 | 2007-12-16 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
| CA2625681C (en) | 2005-10-12 | 2016-08-02 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
| WO2008037257A2 (en) | 2006-09-26 | 2008-04-03 | Genmab A/S | Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP2191842A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
| EP2191843A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
| EP2191841A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
| EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| JP7687956B2 (ja) * | 2019-03-15 | 2025-06-03 | モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 自己抗体介在性自己免疫疾患の処置のための、抗ｃｄ３８抗体及びその医薬組成物 |
-
2022
- 2022-07-18 TW TW111126828A patent/TW202321303A/zh unknown
- 2022-07-19 EP EP22754062.2A patent/EP4373574A1/en active Pending
- 2022-07-19 IL IL309940A patent/IL309940A/en unknown
- 2022-07-19 US US18/580,460 patent/US20240343822A1/en active Pending
- 2022-07-19 AU AU2022315512A patent/AU2022315512A1/en active Pending
- 2022-07-19 KR KR1020247003421A patent/KR20240035816A/ko active Pending
- 2022-07-19 MX MX2024000872A patent/MX2024000872A/es unknown
- 2022-07-19 JP JP2024502640A patent/JP2024525870A/ja active Pending
- 2022-07-19 CA CA3225908A patent/CA3225908A1/en active Pending
- 2022-07-19 WO PCT/EP2022/070162 patent/WO2023001804A1/en not_active Ceased
-
2024
- 2024-01-17 CL CL2024000146A patent/CL2024000146A1/es unknown
- 2024-11-11 CL CL2024003440A patent/CL2024003440A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024525870A (ja) | 2024-07-12 |
| AU2022315512A1 (en) | 2024-01-25 |
| KR20240035816A (ko) | 2024-03-18 |
| TW202321303A (zh) | 2023-06-01 |
| CL2024000146A1 (es) | 2024-05-31 |
| IL309940A (en) | 2024-03-01 |
| EP4373574A1 (en) | 2024-05-29 |
| WO2023001804A1 (en) | 2023-01-26 |
| CL2024003440A1 (es) | 2025-02-21 |
| CA3225908A1 (en) | 2023-01-26 |
| US20240343822A1 (en) | 2024-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201690905A1 (ru) | Специфические антитела против cd38 для лечения злокачественных новообразований у человека | |
| MX2020004023A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
| MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| MX2024000872A (es) | Tratamiento de la nefropatia membranosa mediada por autoanticuerpos anti-pla2r. | |
| MX2019002510A (es) | Metodos para usar un anticuerpo biespecifico que reconoce el factor de coagulacion ix y/o el factor de coagulacion ix activado y el factor de coagulacion x y/o factor de coagulacion x activado. | |
| NZ720736A (en) | Antibody drug conjugates (adcs) with kinesin spindel protein (ksp) | |
| MX2016010504A (es) | Metodos para el tratamiento de pacientes con hipercolesterolemia que no esta controlada adecuadamente por una terapia con estatinas de dosis moderada referencia cruzada a solicitudes relacionas. | |
| SG184339A1 (en) | Botulinum toxin dosage regimen for chronic migraine prophylaxis | |
| MX2023014187A (es) | Un inhibidor de receptor de interleucina-4 para usarse en el tratamiento de la dermatitis atopica severa. | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| MX2022008478A (es) | Combinaciones de brimonidina de dosis baja y usos de las mismas. | |
| MX2021011181A (es) | Anticuerpos anti-cd38 y sus composiciones farmacéuticas para el tratamiento de la enfermedad autoinmune mediada por autoanticuerpos. | |
| MX2022005624A (es) | Tratamiento de vomito y nausea con una dosis minima de olanzapina. | |
| MX2024001954A (es) | Anticuerpos il-13 para el tratamiento de la dermatitis atopica. | |
| EA201792294A1 (ru) | Комбинированное лечение (варианты) с применением серибантумаба | |
| MX2023014484A (es) | Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion. | |
| EA201592058A1 (ru) | Применение ландиолола гидрохлорида в длительном лечении тахиаритмии | |
| EA201691055A1 (ru) | Препараты и способы лечения gd2-положительного рака | |
| PH12016500677A1 (en) | Specific anti-cd38 antibodies for treating human cancers | |
| EP4252847A3 (en) | Regimens and methods of treating multiple sclerosis using ofatumumab | |
| EA201690903A1 (ru) | Лечение глаукомы с использованием лаквинимода | |
| RU2014141112A (ru) | Метаболит илоперидона для применения при лечении психических расстройств | |
| EP4696381A3 (en) | Medicine | |
| MY180772A (en) | Novel therapeutic mirtazapine combinations for use in pain disorders | |
| EA202192716A1 (ru) | Состав вагинальных таблеток |